The Role Of Subclinical Infection And Cytokines In Preterm Parturition
亚临床感染和细胞因子在早产中的作用
基本信息
- 批准号:9150098
- 负责人:
- 金额:$ 2080.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AbdomenAccountingAcuteAdipose tissueAffectAgeAmniotic FluidAmpicillinAnaerobic BacteriaAngiogenic FactorAntibiotic TherapyAntibioticsBedside TestingsBiological MarkersBiological ProcessBiometryBirthBloodCeftriaxoneCephalosporinsClarithromycinClinicalCombined AntibioticsDataDepositionDevelopmentDiagnosisDifferential DiagnosisDiseaseEndoglinEnergy MetabolismEnzyme-Linked Immunosorbent AssayExonsFetal DeathFetal Growth RetardationFetal WeightFetusFibrinFloorGene ChipsGene ExpressionGene Expression ProfileGenesGlucoseGoalsHistologicHumanImmunoassayInfantInfarctionInfectionInflammationInflammatoryInjuryInterleukin-6InterventionKetone BodiesLactic acidLateralLesionLive BirthMalnutritionMeasuresMessenger RNAMetabolicMetabolismMethodsMetronidazoleMolecularMorbidity - disease rateMothersNeonatalNonesterified Fatty AcidsNutrientOutcomePathologic ProcessesPatientsPerformancePerinatalPerinatologyPhysiciansPlacentaPlasmaPlayPravastatinPre-EclampsiaPregnancyPregnancy ComplicationsPregnancy OutcomePregnant WomenPremature BirthPremature LaborPremature Rupture Fetal MembranesPreventionProblem SolvingProcessProductionProteinsRNA SplicingRecurrenceRegimenRegulationReportingResearchRetrospective StudiesRiskRisk AssessmentRoleRuptureScienceSecond Labor StageSmall for Gestational Age InfantSpecificitySpliced GenesStagingSyndromeTechniquesTimeUreaplasmaVisceralWomanadverse outcomeamniotic cavityantimicrobialantimicrobial drugbaseclinical practicecostcytokinedifferential expressionfetalimprovedindexingintraamniotic infectionmicrobialmortalitymyometriumneonatal sepsisperinatal outcomesprematurepreterm premature rupture of membranespreventrapid diagnosissubcutaneoustherapy designtime use
项目摘要
Antibiotic Treatment of Patients with Preterm Prelabor Rupture of Membranes: Premature rupture of membranes (PROM) affects 10% of all pregnant women and preterm PROM occurs in 1% of all gestations. PROM in the preterm gestation accounts for 30% of all preterm births. The administration of antibiotics to patients with preterm PROM has become the standard of practice and is effective in increasing the duration of the latency period and reducing the rate of clinical chorioamnionitis and neonatal sepsis. Studies reported by our Branch have provided evidence that antibiotics administration do not eradicate subclinical intra-amniotic infection in patients with preterm PROM or prevent subsequent infection. This led us to conduct a retrospective study of the outcome of pregnancy in patients given conventional antimicrobial vs. a new combination of antibiotics effective against ureaplasma species and anaerobic bacteria. We compared perinatal outcomes in 314 patients with PROM <34 weeks receiving antimicrobial regimen 1 (ampicillin and/or cephalosporins; n=195) vs. regimen 2 (ceftriaxone, clarithromycin and metronidazole; n=119). The outcomes of preterm PROM treated with standard antibiotic administration vs. a new combination proved that the new combination consisting of ceftriaxone, clarithromycin, and metronidazole prolonged the latency period, reduced acute histologic chorioamnionitis and funisitis and improved neonatal outcomes in patients with preterm PROM. These studies call for a reexamination of the current clinical practice and suggest that alternative antimicrobial agents may be more effective in this common complication of pregnancy (1).
Biomarkers to Predict Induced Preterm Delivery: Inducted or induced preterm delivery account for 30% of all preterm births and occur because of maternal and/or fetal indications such as preeclampsia or intrauterine growth restriction. Small-for-gestational-age (SGA) fetuses could be constitutionally small or be the result of intrauterine malnutrition. The differential diagnosis between these two conditions has been a challenge. This year, we reported a study which determined whether maternal plasma concentrations of specific biomarkers (angiogenic and anti-angiogenic factors) can predict which mothers diagnosed with suspected SGA will develop preeclampsia or require an indicated early preterm delivery (≤34 weeks of gestation); and whether risk assessment performance is improved using these proteins in addition to clinical factors and Doppler parameters. This study included women with singleton pregnancies diagnosed with suspected SGA (estimated fetal weight <10th percentile) between 24 and 34 weeks of gestation (n=314). We found that the biomarkers measured in maternal blood between 24-34 weeks of gestation can indeed identify the majority of mothers diagnosed with suspected SGA who subsequently developed preeclampsia or those who required preterm delivery ≤ 34 weeks of gestation. Moreover, the addition of these biomarkers to other clinical parameters improved the prediction of preterm delivery (2).
A Point of Care Test for Interleukin-6 in Amniotic Fluid: Preterm PROM accounts for 30-40% of spontaneous deliveries <37 weeks of gestation and is a major cause of perinatal morbidity and mortality. Amniotic fluid (AF) interleukin-6 (IL-6) concentrations can identify patients with intra-amniotic inflammation, at risk of impending preterm delivery and adverse pregnancy outcome. The conventional method to determine IL-6 concentrations in AF is an enzyme-linked immunosorbent assay (ELISA). However, this technique is not available in clinical settings and the results may take several days to acquire. A lateral flow-based immunoassay, or point of care (POC) test, has been developed to solve these problems. We conducted a study to compare the performance of AF IL-6 determined by the POC test to that determined by ELISA for the identification of intra-amniotic inflammation, and for assessing risk of spontaneous preterm delivery in patients with preterm PROM. This study included 56 women with singleton pregnancies who presented with preterm PROM. The findings were: 1) a positive POC test for AF IL-6 concentrations had 97% sensitivity and 96% specificity for the identification of intra-amniotic inflammation, as defined by ELISA; and 2) results of the POC test were equivalent to those determined by ELISA in identifying patients with microbial invasion of amniotic cavity, as well as those with acute inflammatory lesions of the placenta. These findings suggest that a POC test for AF concentrations of IL-6 can be used in place of ELISA for the identification of intra-amniotic inflammation in women with preterm PROM. Results can be available within 20 minutes this makes it possible to implement interventions designed to treat intra-amniotic inflammation and improve pregnancy outcome (3).
Prevention of Fetal Death with the Use of Statins: Massive perivillous fibrin deposition of the placenta or maternal floor infarction is a serious condition associated with recurrent complications including fetal death and severe fetal growth restriction. There is no method to evaluate the risk of adverse outcomes in subsequent pregnancies, or effective prevention. Recent observations reported by our Branch discovered that maternal floor infarction is characterized by an imbalance in angiogenic/anti-angiogenic factors in early pregnancy. Statins can increase the production of angiogenic factors and inhibit anti-angiogenic forces. We report for the first time the use of statins to prevent recurrent fetal death. Abnormalities of the anti-angiogenic factor, sVEGFR-1, and soluble endoglin were detected early in the index pregnancy, and treatment with pravastatin corrected the abnormalities. Treatment resulted in a live birth infant near term who had normal biometric parameters and development milestones at the age of 2. This is the first reported successful use of pravastatin to reverse an angiogenic/anti-angiogenic imbalance and prevent fetal death. Whether other interventions can reverse the anti-angiogenic state associated with massive perivillous fibrin deposition of the placenta remains to be established (4).
Characterization of Visceral and Subcutaneous Adipose Tissue Transcriptome: Parturition imposes an increased energy demand on the laboring woman. Labor is characterized by increased concentrations of nutrients including glucose, free fatty acids, ketone bodies, and lactic acid. There is an approximately 3-fold increase in whole body glucose utilization during labor and delivery and, as expected, energy expenditure of the parturient women in the second stage of labor is 40% higher compared to the first stage. Examination of the human myometrium transcriptome revealed that biological processes related to metabolism were among the molecular functions enriched in the differentially expressed genes between pregnant women with and without spontaneous term labor. We undertook a study to determine gene expression and splicing changes associated with parturition and regions (visceral vs. subcutaneous) of the adipose tissue of pregnant women. The transcriptome of visceral and abdominal subcutaneous adipose tissue from pregnant women at term with (n=15) and without (n=25) spontaneous labor was profiled with Affymetrix GeneChip Human Exon 1.0 ST array. Overall gene expression changes and differential exon usage rate were compared between patient groups and adipose tissue regions (paired analyses). We showed, for the first time, evidence that mRNA splicing and processing in the subcutaneous adipose tissue of women in labor compared to those without labor. Collectively, our data indicate that adipose tissue may play a role in metabolic regulation in human parturition (5).
早产胎膜破裂患者的抗生素治疗:胎膜早破(PROM)影响10%的孕妇,早产胎膜早破发生率为1%。早胎早破占所有早产的30%。对早产胎膜早破患者应用抗生素已成为惯例,可有效延长潜伏期,降低临床绒毛膜羊膜炎和新生儿败血症的发生率。我们分会报告的研究提供了证据,表明抗生素的使用并不能根除早产儿羊膜早破患者的亚临床羊膜内感染,也不能预防随后的感染。因此,我们进行了一项回顾性研究,比较了使用常规抗菌药物的患者与使用对脲原体和厌氧菌有效的新型抗生素组合的妊娠结局。我们比较了314例胎膜早破<34周的患者接受抗菌方案1(氨苄西林和/或头孢菌素,n=195)和方案2(头孢曲松、克拉霉素和甲硝唑,n=119)的围产儿结局。标准抗生素与甲硝唑联合治疗早产儿胎膜早破的结果证明,头孢曲松、克拉霉素和甲硝唑联合治疗可延长胎膜早破患者的潜伏期,减少急性组织学绒毛膜羊膜炎和羊膜炎,改善新生儿预后。这些研究要求对目前的临床实践进行重新检查,并建议替代抗菌药物可能对这种常见的妊娠并发症更有效(1)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERTO ROMERO其他文献
ROBERTO ROMERO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERTO ROMERO', 18)}}的其他基金
CANDIDATE GENE ANALYSIS OF ADVERSE OBSTETRICAL OUTCOMES
不良产科结局的候选基因分析
- 批准号:
7420626 - 财政年份:2006
- 资助金额:
$ 2080.52万 - 项目类别:
CANDIDATE GENE ANALYSIS OF ADVERSE OBSTETRICAL OUTCOMES
不良产科结局的候选基因分析
- 批准号:
7181280 - 财政年份:2005
- 资助金额:
$ 2080.52万 - 项目类别:
The Role Of Subclinical Infection And Cytokines In Preterm Parturition
亚临床感染和细胞因子在早产中的作用
- 批准号:
8941476 - 财政年份:
- 资助金额:
$ 2080.52万 - 项目类别:
The Role Of Subclinical Infection And Cytokines In Prete
亚临床感染和细胞因子在 Prete 中的作用
- 批准号:
7334071 - 财政年份:
- 资助金额:
$ 2080.52万 - 项目类别:
The Role Of Subclinical Infection And Cytokines In Preterm Parturition
亚临床感染和细胞因子在早产中的作用
- 批准号:
7968617 - 财政年份:
- 资助金额:
$ 2080.52万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 2080.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 2080.52万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 2080.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 2080.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 2080.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 2080.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 2080.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 2080.52万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 2080.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 2080.52万 - 项目类别:














{{item.name}}会员




